Pfizer’s Ibrance Is First CDK4/6 Inhibitor To Show Benefit In HR+, HER2+ Breast Cancer
The Phase III PATINA trial showed Ibrance added to typical HER2+ breast cancer therapy extended progression-free survival by 15 months.
The Phase III PATINA trial showed Ibrance added to typical HER2+ breast cancer therapy extended progression-free survival by 15 months.